Trial intelligence / Profile preview

Bosentan Open-label Extension in Systemic Sclerosis-associated Interstitial Lung Disease

2004-000631-28Phase 3Completed

Sponsor: Actelion Pharmaceuticals Ltd
Start: Sep 2004
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, open-label, single-arm trial of bosentan in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), sponsored by Actelion Pharmaceuticals Ltd. Started Sep 2004; status: completed.

Drugs

bosentan

Conditions

pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)

Beyond the preview

Go deeper on 2004-000631-28.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-000631-28.